1. Monday
ASHLEIGH MONDAY, CRC
COVENANT CLINICAL RESEARCH, PA
2829 Babcock Rd., Suite 540
San Antonio, Texas 78229
amonday@covenantclinicalresearch.com
_______________________________________________________________________
_
Phone (210) 614-3030
Fax (210) 614-7901
EDUCATION
2014-Present Northwest Vista Alamo College
Completing AAS- Clinical Research
MEDICAL EXPERIENCE
March 2015-Present Clinical Research Coordinator
Covenant Clinical Research, PA
2829 Babcock Rd. , Ste 540
San Antonio, Texas 78229
May 2014-March 2015 Medical Billing
Ronald K. Garcia, M.D., PA
2829 Babcock Rd., Ste 540
San Antonio, Texas 78229
January 2010-May 2014 Medical Receptionist
Ronald K Garcia, M.D., PA
2829 Babcock Rd., Ste 540
San Antonio, Texas 78229
CERTIFICATION AND TRAINING
2015 Transportation of Dangerous Goods
2015 CITI-GCP Training
2015 CITI-IRB Training
2015 National Institute of Health Human Participants Protection Education
1

2. Monday
CLINICAL RESEARCH EXPERIENCE
1. “A 24 Week International, Multi-center, randomized, Parallel group, Double-Blind Trial to
Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate
Release Monotherapy in Adult Subjects with Type 2 Diabetes who have Inadequate Glycemic
Control with Diet and Exercise”. Principal Investigator: Ronald K. Garcia, M.D.
Sponsored by Bristol-Myers Squibb Research and Development.
2. “A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in
Subjects with Type 2 Diabetes at High Risk of Cardiovascular Events”.
Principal Investigator: Ronald K. Garcia, M.D.
Sponsored by Novo Nordisk
3. “ Efficacy and Safety of Semaglitude Once Weekly Versus Insulin
Glargine Once Daily as Add On to Metformin with or without Sulphonylurea in Insulin-Naïve
Subjects with Type 2 Diabetes”.
Principal Investigator: Ronald K. Garcia, M.D.
Sponsored by Novo Nordisk
4. “ A Multicenter, International, Randomized, Parallel Group,
Double-blind, Placebo Controlled Cardiovascular Safety & Renal Microvascular OutcomE
Study with XXXXgliptin, 5mg Once Daily in Patients with Type 2 Diabetes Mellitus at
High Vascular Risk. CARMELINA” Principal Investigator: Ronald K. Garcia, M.D.
Sponsored by Boehringer Ingelheim
5. “A 26-week International, Multicenter, Randomized, Double-
Blind, Active Controlled, Parallel Group, Phase 3b Trial with a Blinded 26 week Long
Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered
with Dapagliflozin in Combination with Metformin in Adult Patients with Type 2 Diabetes
Who Have Inadequate Glycemic Control on Metformin Therapy Alone”
Principal Investigator: Ronald K. Garcia, M.D.
Sponsored by Bristol Myers Squibb
2